JPRN-jRCT2080221694未知3 期
Study of combination therapy with SYR-322
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点目标入组 179 人开始时间: 2012年1月20日最近更新:
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 179
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •1. The subject is an outpatient.
- •2. The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
排除标准
- •1. The subject has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.
- •2. The subject is considered ineligible for the study for any other reason by the investigator or subinvestigator.
研究者
相似试验
已完成
不适用
A Phase 2/3 Study of SYR-322 as an Add-on to a MetformiType 2 diabetes mellitusJPRN-UMIN000001394Takeda Pharmaceutical Company Limited240
未知
2 期
A Phase 2/3 Study of SYR-322 as an Add-on to a MetformiType 2 diabetes mellitusJPRN-jRCT2080220606Takeda Pharmaceutical Company Limited240
未知
2 期
A phase II/III study of SYR-322 in subject with diabetesDiabetes mellitusJPRN-jRCT2080220871Takeda Pharmaceutical Company Limited
尚未招募
不适用
A phase 2 study of combination therapy with irinotecan/ S-1 (IRIS) plus panitumumab as second-line chemotherapy for metastatic colorectal cancercolonrectal cancerJPRN-UMIN000004659The University of Tokushima Graduate School35
已完成
2 期
Phase II study of combination therapy with S-1 plus cetuximab in patients with EGFR positive KRAS wild type unresectable colorectal cancer, who had previously received on irinotecan, oxaliplatin and fluoropyrimidine(KSCC0901).Colorectal cancerJPRN-UMIN000002475Kyushu Study group of Clinical Cancer39